UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~September 425, 2017

______________

AOXING PHARMACEUTICAL COMPANY, INC.

(Exact name of registrant as specified in its charter)

______________

Florida	0-24185	65-0636168
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
of Incorporation)	File Number)	Identification No.)

1098 Foster City Blvd., Suite 106-810, Foster City, CA 94404

(Address of Principal Executive Office) (Zip Code)

(646) 367 1747

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Indicate~~Item ~~by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230~~3.~~405~~01 Notice of ~~this~~Delisting ~~chapter)~~ or ~~Rule~~Failure ~~12b-2~~to ofSatisfy ~~the~~a ~~Securities~~Continued ~~Exchange~~Listing ~~Act~~Rule ofor ~~1934 (§240.12b-2 of this chapter).~~Standard

~~Emerging~~ On ~~growth~~September ~~company ☐~~25, 2017, Aoxing Pharmaceutical Company, Inc. notified the NYSE MKT that the Company's Board of Directors has determined to remove the Company's common stock from the NYSE MKT by filing a Form 25 Notification of Removal on October 6, 2017, which will become effective on October 16, 2017. Promptly following the effective date of the Form 25, the Company will also file a Form 15 Notice of Termination of Registration, which will, when effective, terminate the Company's obligation to file reports with the Securities and Exchange Commission.

IfOn anSeptember ~~emerging~~25, ~~growth company~~2017, ~~indicate~~Aoxing byPharma ~~check~~issued ~~mark~~a ifpress ~~the~~release ~~registrant~~describing ~~has elected not to use~~ the ~~extended~~aforesaid ~~transition~~plans. ~~period~~A ~~for~~copy ~~complying~~of ~~with~~the ~~any~~press ~~new~~release oris ~~revised~~being ~~financial~~filed ~~accounting~~as ~~standards~~an ~~provided~~exhibit ~~pursuant~~ to ~~Section~~this ~~13(a) of the Exchange Act~~Report. ☐

Item 59.0201 Financial ~~Departure~~Statements ofand ~~Directors or Certain Officers; Appointment of Certain Officers~~Exhibits

On August 4, 2017 Zheng James Chen resigned from his position as the Registrant's Chief Financial Officer. On August 4, 2017, the Board of Directors appointed Guoan Zhang to serve as the Registrant's Chief Financial Officer,. Mr. Zhang has been the Registrant's Senior Vice President of Finance since June 2010 and Chief Accounting Officer since March 2010. Mr. Zhang also served as the Registrant's Acting Chief Financial Officer from July 2012 to December 2014 and November 30, 2015 to January 27, 2016.Exhibits

99.1 Press release dated September 25, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Aoxing Pharmaceutical Company, Inc.
Date: August 4, 2017	By:	/s/ Zhenjiang Yue Zhenjiang Yue, Chief Executive Officer
Date: September 25, 2017	By:	/s/ Zhenjiang Yue Zhenjiang Yue, Chief Executive Officer

Filing Compare · AOXING PHARMACEUTICAL COMPANY, INC.